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To assess the prevalence of high on-clopidogrel platelet reactivity (HCPR) in patients
with ischaemic stroke or transient ischaemic attack (IS/TIA), their outcome and genetic
basis of on-treatment response variability in IS/TIA patients.
Methods
We conducted a comprehensive search of PubMed and EMBASE from their inceptions
to March 9, 2019. Studies that reported absolute numbers/percentages of HCRP at any
time point after IS/TIA onset evaluated with any type of platelet function tests, clinical
outcomes and genotyping data were included.
Results
Among 21 studies of 4312 IS/TIA patients treated with clopidogrel, the pooled
prevalence of HCPR was 28% (95%CI: 24-32%; high heterogeneity: I  2  =88.2%,  p
<0.001). Heterogeneity degree diminished across groups defined by the HCPR testing
method. Clopidogrel non-responder IS/TIA patients had poorer outcome compared to
responders (RR=2.09, 95%CI: 1.61–2.70;  p  =0.036; low heterogeneity across studies:
I  2  =27.4%,  p  =0.210). IS/TIA carriers of  CYP2C19*2  or  CYP2C19*3  loss of
function alleles had a higher risk of HCPR compared to wild type (RR=1.69, 95%CI:
1.47–1.95;  p  <0.001; I  2  =0.01%,  p  =0.475).
Conclusions
This systematic review shows a high prevalence of clopidogrel resistance in IS/TIA and
poor outcome in these patients.  CYP2C19  polymorphisms may potentially influence
clopidogrel resistance.
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Objectives: To assess the prevalence of high on-clopidogrel platelet reactivity (HCPR) in 2 
patients with ischaemic stroke or transient ischaemic attack (IS/TIA), their outcome and 3 
genetic basis of on-treatment response variability in IS/TIA patients.   4 
Methods: We conducted a comprehensive search of PubMed and EMBASE from their 5 
inceptions to March 9, 2019. Studies that reported absolute numbers/percentages of HCRP 6 
at any time point after IS/TIA onset evaluated with any type of platelet function tests, clinical 7 
outcomes and genotyping data were included.  8 
Results: Among 21 studies of 4312 IS/TIA patients treated with clopidogrel, the pooled 9 
prevalence of HCPR was 28% (95%CI: 24-32%; high heterogeneity: I2=88.2%, p<0.001). 10 
Heterogeneity degree diminished across groups defined by the HCPR testing method. 11 
Clopidogrel non-responder IS/TIA patients had poorer outcome compared to responders 12 
(RR=2.09, 95%CI: 1.61–2.70; p=0.036; low heterogeneity across studies: I2=27.4%, p=0.210). 13 
IS/TIA carriers of CYP2C19*2 or CYP2C19*3 loss of function alleles had a higher risk of HCPR 14 
compared to wild type (RR=1.69, 95%CI: 1.47–1.95; p<0.001; I2=0.01%, p=0.475).  15 
Conclusions: This systematic review shows a high prevalence of clopidogrel resistance in 16 
IS/TIA and poor outcome in these patients. CYP2C19 polymorphisms may potentially 17 
influence clopidogrel resistance. 18 
  19 




Excessive platelet activation plays a major role in the pathophysiology of ischaemic stroke1-21 
12. Clopidogrel has been shown to be superior to aspirin in platelet inhibition and reducing 22 
the risk of ischaemic stroke13. It is metabolized by cytochrome P450 and the active metabolite 23 
irreversibly binds to platelet surface receptor P2Y12 inhibiting adenosine diphosphate 24 
induced platelet activation14. However, the antiplatelet response to clopidogrel is highly 25 
variable15. The reported prevalence of clopidogrel resistance, also termed “high on-26 
clopidogrel platelet reactivity (HCPR)”, ranges from 16% to 65%16-19. This wide variation in 27 
clopidogrel resistance prevalence is attributed to the profile of the studied population20 and 28 
a lack of consensus on threshold values to define HCPR using different assays which include 29 
for example, VerifyNow P2Y12, light transmission aggregometry (LTA), multiple-electrode 30 
impedance aggregometry (MEA), vasodilator-stimulated phosphoprotein (VASP), 31 
thromboelastography (TEG) and flow cytometry. Causes for decreased platelet inhibition by 32 
clopidogrel are multifactorial and include genetic, cellular and co-morbid clinical factors21-24.  33 
Studies of ischaemic stroke patients with clopidogrel resistance have shown an association 34 
with early neurological deterioration and recurrent ischaemic episode with poor recovery25. 35 
Similarly, patients displaying HCPR have been shown to be at higher risk of thromboembolic 36 
events during and after carotid revascularisation26.  37 
In this article, we undertook a systematic review and meta-analysis of the prevalence of HCPR 38 
in patients with ischaemic stroke or transient ischaemic attack (IS/TIA), their outcome and 39 
the genetic basis of on-treatment response variability in IS/TIA patients.   40 
 3 
Methods 41 
This meta-analysis is presented according to the Preferred Reporting Items for Systematic 42 
Reviews and Meta-Analyses (PRISMA) guidelines27 for systematic reviews and meta-analyses. 43 
We searched PUBMED and EMBASE for publications from inception up to March 9, 2019, and 44 
used the search terms (Clopidogrel*/ resistance*) OR (high*/ OR therapy* OR treatment* OR 45 
therapeutics.mp OR therapeutics*/ blood platelets OR blood*/ platelets* OR blood platelets* 46 
OR platelet*/ reactivity*) AND (stroke OR stroke*) OR (ischemic attack, transient OR 47 
ischemic*/ attack*/ transient* OR transient ischemic attack* OR 48 
transient*/ischemic*/attack*). We further performed a search of the Cochrane library, and 49 
ClinicalTrials.gov, and a manual search of references from all identified publications.  50 
Two authors (VA, XH) identified studies eligible for further review by performing an initial 51 
screen of identified titles or abstracts. We restricted studies to those including patients with 52 
ischaemic stroke or TIA on Clopidogrel; those with coronary artery disease were excluded. 53 
Studies were considered for inclusion in the meta-analysis if they reported absolute 54 
numbers/percentages of HCPR at any time point after ischaemic stroke or TIA onset evaluated 55 
with any type of platelet function test, any type of study design with or without reported 56 
clinical outcomes or genotyping data. Any disagreement was reviewed by a third reviewer 57 
(ACP) and resolved by consensus. Initial screening revealed 33 potential studies and full-text 58 
article assessment excluded studies on the same cohort. Twenty-one studies were included 59 
for meta-analysis (Figure 1).   60 
CYP2C19*2 and CYP2C19*3 alleles that result in impaired metabolism of CYP2C19 substrates 61 
were entitled as loss-of-function alleles28. Patients with at least 1 loss-of-function alleles 62 
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(hetero- or homozygous for CYP2C19*2 or CYP2C19*3) were classified as loss-of-function 63 
allele carriers. Of twenty-one studies included for meta-analysis, eight studies provided data 64 
on CYP2C19 loss of function allele carrier status in IS/TIA patients and clinical outcomes 65 
(Figure 4). Of eight studies, only four analysed platelet resistance and clinical outcome in 66 
CYP2C19 loss of function allele carriers, and therefore this was not included in Figure 4 67 
(Supplementary Table 1).  68 
The primary end point was HCRP pooled proportion and outcome in clopidogrel-treated 69 
IS/TIA. The secondary endpoint was the association between CYP2C19*2 and CYP2C19*3 loss 70 
of function allele carrier status and HCPR in IS/TIA. Statistical analyses were performed using 71 
STATA software (version 15.0, Stata Corporation, College Station, TX). Pooled prevalence of 72 
HCPR in IS/TIA cohort across studies was derived. Pooled risk ratios (RR) and 95% confidence 73 
intervals (CIs) were calculated as the overall measure of efficacy of clopidogrel response using 74 
random-effects models. Two-sided probability values of <0.05 were considered statistically 75 
significant. Each analysis was accompanied by the assessment of the corresponding 76 
heterogeneity evaluated by the I2 statistic; the Cochrane Q (χ2) statistic assessed 77 
heterogeneity between studies. Potential publication bias of studies with different sample 78 
sizes was examined by visual inspection of funnel plots and trim-and-fill analysis. The 79 
guidelines from https://uk.cochrane.org/news/meta-analysis-what-why-and-how were 80 
followed. 81 
Results 82 
Our search identified 21 potentially relevant studies with a total of 4312 ischaemic stroke 83 
and/or TIA patients on Clopidogrel. Study sizes ranged from 62 to 465 stroke or TIA patients.  84 
 5 
Characteristics of the studies are summarised on the Supplementary Table 2. In the overall 85 
analysis of all included studies, the pooled prevalence of HCPR was 28% (95%CI: 24–32%). 86 
However, the prevalence reported between studies presented great variability as 87 
demonstrated by substantial heterogeneity (I2 = 88.2%, Cochran Q p<0.001) (Figure 2). 88 
The main finding is the significant disparity in many aspects across the studies not only in 89 
outcome measure, but also in the patients included, their demographics, the dose of 90 
Clopidogrel, the timing of the tests, the laboratory methods used, the definition of HCPR, and 91 
so on. In order to explain the heterogeneity, we did several analyses by grouping studies 92 
according to factors such as ethnicity (Supplementary Figure 1 and Supplementary Table 2), 93 
and laboratory methods assessing HCPR (Supplementary Table 1 and Supplementary Figure 94 
3). Supplementary Figure 2 refers to subgroup analysis on the prevalence of HCPR according 95 
to use carotid artery stenting.  96 
Heterogeneity only reduced amongst studies using multiple-electrode impedance 97 
aggregometry (MEA), thromboelastography (TEG) and vasodilator-stimulated 98 
phosphoprotein (VASP) methods (Table 1); and   improved with analysis of studies using light 99 
transmission aggregometry (LTA) testing with similar cut-off points defining HCPR 100 
(Supplementary Table 1 and Supplementary Figure 4).  101 
In the analysis of eight studies (total of 1887 IS/TIA patients on clopidogrel) providing data on 102 
outcome including recurrent stroke or other vascular events, increased modified Rankin Scale 103 
(mRS) or National Institutes of Health Stroke Scale (NIHSS) and death, IS/TIA patients with 104 
HCPR had poorer outcome compared to clopidogrel responders (RR = 2.09, 1.61–2.70, 105 
p=0.036) (Figure 3 and Supplementary Table 3).  106 
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From the analysis of eight studies providing data on genotyping, IS/TIA carriers of CYP2C19 107 
loss of function allele (*2 or *3) had a higher risk for HCPR (RR=1.69, 95%CI: 1.47–1.95; 108 
p<0.001; I2=0.01%, p=0.475) (Figure 4). 109 
Discussion 110 
The present report is to our knowledge the first meta-analysis that determines the prevalence 111 
of HCPR in IS/TIA patients and shows a positive association between the presence of HCPR 112 
and poor outcome including recurrent stroke or other vascular events, stroke progression or 113 
death. This finding is consistent with previously published systematic reviews and meta-114 
analyses that reported an increased risk of cardiovascular events in patients with HCPR16. 115 
Meta-analyses in patients with acute coronary syndrome29 who underwent percutaneous 116 
coronary intervention and stenting had a prevalence of HCPR of 21%, with a pooled OR of 117 
cardiovascular events of 8.0, which is similar to our finding.  However, a peripheral vascular 118 
disease30 meta-analysis reported a prevalence of HCPR of 65%, which is much higher than our 119 
result.  120 
There is significant heterogeneity evident across the studies. In particular, the laboratory 121 
methods for testing clopidogrel resistance and the definition of HCPR varied from study to 122 
study. Currently, multiple laboratory and point of care platelet function testing are used 123 
across the world. A recent review31 comparing existing platelet function tests has emphasised 124 
that non-standardised use of these tests and the lack of a proper definition is at least partly 125 
responsible for the disparity of the prevalence reported in studies. In one guideline32 that 126 
attempted to standardise the definition of HCPR, the author argued that cut-off values to 127 
define HCPR are better determined by the individual laboratory, rather than providing an 128 
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arbitrary value generated from previous studies. That report also recommended that multiple 129 
assessments of the patients should be done in the same laboratory if possible, to provide 130 
meaningful interpretation. The same group33 suggested additional clinical information and 131 
genotyping besides a platelet function test may be a better prediction of the risk of recurrent 132 
thromboembolic events.  133 
In all the included studies, there were significant differences in clinical factors such as 134 
ethnicity, age, and co-morbidities, which probably have contributed to the heterogeneity of 135 
the analysis. In subgroup analysis for Asian/Non-Asian, IS/TIA plus or minus carotid artery 136 
stent, this heterogeneity did not dissipate. However, the subgroup analysis of laboratory 137 
methods did show much less heterogeneity, but the number of studies in each group was 138 
small so the results must be interpreted with caution. 139 
A similar pattern of disparity was observed in analysis of the genetic studies. We nevertheless 140 
found that a significant proportion of IS/TIA patients with HCPR were CYP2C19 loss-function 141 
allele carriers. Previous studies showed that among patients with ischemic stroke or TIA 142 
treated with clopidogrel, carriers of CYP2C19 loss-of-function alleles are at increased risk of 143 
new stroke and composite vascular events in comparison with noncarriers, whereas bleeding 144 
risk is similar34. Similarly,  the metanalysis35 of acute coronary syndrome (ACS) patients who 145 
were CYP2C19 loss-of-function carriers, found them to have an increased risk of myocardial 146 
infarct (MI), stent occlusion and ischaemic stroke, which supports the conclusion that 147 
CYP2C19 has an important role in clopidogrel metabolism. However, not all patients with 148 
HCPR develop recurrent vascular events. The factors relating to this may not rest solely on 149 
pharmacokinetic aspects of clopidogrel metabolism but may also involve other genetic 150 
variation36. On the present evidence, CYP2C19 genotyping may be a useful addition to the 151 
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individualised risk assessment to predict whether patients on clopidogrel are more at risk of 152 
recurrent vascular events and merit treatment with an alternative antiplatelet agent. 153 
However, further research is needed to assess the applicability of CYP2C19 genotyping on a 154 
routine basis.  155 
Our study has some limitations. First, none of the studies included in the meta-analysis was a 156 
randomised study. Second, medications including proton pump inhibitors intake data among 157 
studies was scanty and therefore was not included to the meta-analysis. Third, platelet 158 
resistance and clinical outcome was not analysed in CYP2C19 loss of function allele carriers 159 
due to limited data among studies.  160 
Clopidogrel resistance has been described for more than a decade, but the quality of 161 
published studies is so variable and heterogeneous that firmer conclusions from this meta-162 
analysis cannot be drawn. However, patients with HCRP need evidence based guidance on 163 
how to approach their management. In order to determine the true potential benefit of 164 
testing for HCPR in the clinical setting, a randomised multicentre study with a single HCPR 165 
definition and centralised laboratory testing is warranted. 166 
Abbreviations 167 
ACS  acute coronary syndrome 168 
CR  clopidogrel responders 169 
CI  confidence intervals 170 
ES  effect size 171 
HCPR  high on clopidogrel platelet reactivity  172 
IS  ischaemic stroke  173 
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LoF   loss of function   174 
LTA   light transmission aggregometry  175 
MEA  multiple-electrode impedance aggregometry  176 
MI  myocardial infarction 177 
PRISMA  Preferred Reporting Items for Systematic Reviews and Meta-Analyses  178 
RR  risk ratios  179 
TEG  thromboelastography  180 
TIA  transient ischaemic attack  181 
VASP   vasodilator-stimulated phosphoprotein  182 
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Figure legends 376 
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Figure 1: Flow chart diagram presenting the selection procedure of eligible studies.  377 
Figure 2: Pooled prevalence of all studies: Heterogeneity chi-squared = 169.69 (d.f. = 20), 378 
p<0.001; I-squared (variation in ES attributable to heterogeneity) = 8788.2%; Estimate of 379 
between-study variance Tau-squared = 0.0069; Test of ES=0 : z= 14.22; p<0.001. References25, 380 
37-56. ID (identification); ES (effect size;) CI, confidence interval. 381 
Figure 3: Overall analysis of all studies providing data on the outcome between non-382 
responders and responders to clopidogrel. References25, 38, 45-48, 50, 55. ID, identification; RR 383 
(relative risk); CI, confidence interval. 384 
Figure 4: HPCR related to CYP2C19 loss of function: Heterogeneity chi-squared =  6.57(d.f. =7) 385 
p = 0.475; I-squared (variation in ES attributable to heterogeneity) =  0.01%; Estimate of 386 
between-study variance Tau-squared =  0.0000; Test of RR=1 : z= 7.32;  p<0.001. References39, 387 
45, 47, 50-53, 55. ID (identification); RR (relative risk); CI (confidence interval). 388 
 389 
Table legends  390 
Table 1. Subgroup analyses on the prevalence of HCPR reported in included studies. 391 
References25, 37-56 392 
Supplementary data 393 
Supplementary Table 1: Laboratory characteristics of the studies included for pooled 394 
proportion analysis. References25, 37-56 395 
Supplementary Table 2: Clinical characteristics of the studies included for pooled proportion 396 
analysis. References25, 37-56 397 
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Supplementary Table 3: Outcome of the HCPR vs clopidogrel responders. References39, 45, 47, 398 
50-53, 55 399 
Supplementary Figure 1: Subgroup analyses on the prevalence of HCPR according to ethnicity. 400 
References25, 37-56. ID (identification); ES (effect size); CI (confidence interval). 401 
Supplementary Figure 2: Subgroup analyses on the prevalence of HCPR according to carotid 402 
artery stenting. References25, 37-56. ID (identification); ES (effect size); CI (confidence interval); 403 
IS (ischaemic stroke); CAS (carotid artery stenting).  404 
Supplementary Figure 3: Subgroup analyses on the prevalence of HCPR according to test. 405 
References25, 37-56. ID (identification); ES (effect size); CI (confidence interval); LTA (light 406 
transmission aggregometry); VASP (vasodilator-stimulated phosphoprotein); TEG 407 
(thromboelastography); MEA (multiple-electrode impedance aggregometry). 408 
Supplementary Figure 4: Subgroup analyses on the prevalence of HCPR according to LTA test 409 
different cut-off points. References 25, 41, 43, 44, 55. ID (identification); ES (effect size); CI 410 
(confidence interval); LTA (light transmission aggregometry); platelet aggregation rate <30% 411 
or <10% are  cut-off points defining HCPR on light transmission aggregation. 412 
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Abstract 1 
Objectives: To assess the prevalence of high on-clopidogrel platelet reactivity (HCPR) in 2 
patients with ischaemic stroke or transient ischaemic attack (IS/TIA), their outcome and 3 
genetic basis of on-treatment response variability in IS/TIA patients.   4 
Methods: We conducted a comprehensive search of PubMed and EMBASE from their 5 
inceptions to March 9, 2019. Studies that reported absolute numbers/percentages of HCRP 6 
at any time point after IS/TIA onset evaluated with any type of platelet function tests, clinical 7 
outcomes and genotyping data were included.  8 
Results: Among 21 studies of 4312 IS/TIA patients treated with clopidogrel, the pooled 9 
prevalence of HCPR was 28% (95%CI: 24-32%; high heterogeneity: I2=88.2%, p<0.001). 10 
Heterogeneity degree diminished across groups defined by the HCPR testing method. 11 
Clopidogrel non-responder IS/TIA patients had poorer outcome compared to responders 12 
(RR=2.09, 95%CI: 1.61–2.70; p=0.036; low heterogeneity across studies: I2=27.4%, p=0.210). 13 
IS/TIA carriers of CYP2C19*2 or CYP2C19*3 loss of function alleles had a higher risk of HCPR 14 
compared to wild type (RR=1.69, 95%CI: 1.47–1.95; p<0.001; I2=0.01%, p=0.475).  15 
Conclusions: This systematic review shows a high prevalence of clopidogrel resistance in 16 
IS/TIA and poor outcome in these patients. CYP2C19 polymorphisms may potentially 17 
influence clopidogrel resistance. 18 
  19 
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 2 
Introduction 20 
Excessive platelet activation plays a major role in the pathophysiology of ischaemic stroke1-21 
12. Clopidogrel has been shown to be superior to aspirin in platelet inhibition and reducing 22 
the risk of ischaemic stroke13. It is metabolized by cytochrome P450 and the active metabolite 23 
irreversibly binds to platelet surface receptor P2Y12 inhibiting adenosine diphosphate 24 
induced platelet activation14. However, the antiplatelet response to clopidogrel is highly 25 
variable15. The reported prevalence of clopidogrel resistance, also termed “high on-26 
clopidogrel platelet reactivity (HCPR)”, ranges from 16% to 65%16-19. This wide variation in 27 
clopidogrel resistance prevalence is attributed to the profile of the studied population20 and 28 
a lack of consensus on threshold values to define HCPR using different assays which include 29 
for example, VerifyNow P2Y12, light transmission aggregometry (LTA), multiple-electrode 30 
impedance aggregometry (MEA), vasodilator-stimulated phosphoprotein (VASP), 31 
thromboelastography (TEG) and flow cytometry. Causes for decreased platelet inhibition by 32 
clopidogrel are multifactorial and include genetic, cellular and co-morbid clinical factors21-24.  33 
Studies of ischaemic stroke patients with clopidogrel resistance have shown an association 34 
with early neurological deterioration and recurrent ischaemic episode with poor recovery25. 35 
Similarly, patients displaying HCPR have been shown to be at higher risk of thromboembolic 36 
events during and after carotid revascularisation26.  37 
In this article, we undertook a systematic review and meta-analysis of the prevalence of HCPR 38 
in patients with ischaemic stroke or transient ischaemic attack (IS/TIA), their outcome and 39 
the genetic basis of on-treatment response variability in IS/TIA patients.   40 
 3 
Methods 41 
This meta-analysis is presented according to the Preferred Reporting Items for Systematic 42 
Reviews and Meta-Analyses (PRISMA) guidelines27 for systematic reviews and meta-analyses. 43 
We searched PUBMED and EMBASE for publications from inception up to March 9, 2019, and 44 
used the search terms (Clopidogrel*/ resistance*) OR (high*/ OR therapy* OR treatment* OR 45 
therapeutics.mp OR therapeutics*/ blood platelets OR blood*/ platelets* OR blood platelets* 46 
OR platelet*/ reactivity*) AND (stroke OR stroke*) OR (ischemic attack, transient OR 47 
ischemic*/ attack*/ transient* OR transient ischemic attack* OR 48 
transient*/ischemic*/attack*). We further performed a search of the Cochrane library, and 49 
ClinicalTrials.gov, and a manual search of references from all identified publications.  50 
Two authors (VA, XH) identified studies eligible for further review by performing an initial 51 
screen of identified titles or abstracts. We restricted studies to those including patients with 52 
ischaemic stroke or TIA on Clopidogrel; those with coronary artery disease were excluded. 53 
Studies were considered for inclusion in the meta-analysis if they reported absolute 54 
numbers/percentages of HCPR at any time point after ischaemic stroke or TIA onset evaluated 55 
with any type of platelet function test, any type of study design with or without reported 56 
clinical outcomes or genotyping data. Any disagreement was reviewed by a third reviewer 57 
(ACP) and resolved by consensus. Initial screening revealed 33 potential studies and full-text 58 
article assessment excluded studies on the same cohort. Twenty-one studies were included 59 
for meta-analysis (Figure 1).   60 
CYP2C19*2 and CYP2C19*3 alleles that result in impaired metabolism of CYP2C19 substrates 61 
were entitled as loss-of-function alleles28. Patients with at least 1 loss-of-function alleles 62 
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(hetero- or homozygous for CYP2C19*2 or CYP2C19*3) were classified as loss-of-function 63 
allele carriers. Of twenty-one studies included for meta-analysis, eight studies provided data 64 
on CYP2C19 loss of function allele carrier status in IS/TIA patients and clinical outcomes 65 
(Figure 4). Of eight studies, only four analysed platelet resistance and clinical outcome in 66 
CYP2C19 loss of function allele carriers, and therefore this was not included in Figure 4 67 
(Supplementary Table 1).  68 
The primary end point was HCRP pooled proportion and outcome in clopidogrel-treated 69 
IS/TIA. The secondary endpoint was the association between CYP2C19*2 and CYP2C19*3 loss 70 
of function allele carrier status and HCPR in IS/TIA. Statistical analyses were performed using 71 
STATA software (version 15.0, Stata Corporation, College Station, TX). Pooled prevalence of 72 
HCPR in IS/TIA cohort across studies was derived. Pooled risk ratios (RR) and 95% confidence 73 
intervals (CIs) were calculated as the overall measure of efficacy of clopidogrel response using 74 
random-effects models. Two-sided probability values of <0.05 were considered statistically 75 
significant. Each analysis was accompanied by the assessment of the corresponding 76 
heterogeneity evaluated by the I2 statistic; the Cochrane Q (χ2) statistic assessed 77 
heterogeneity between studies. Potential publication bias of studies with different sample 78 
sizes was examined by visual inspection of funnel plots and trim-and-fill analysis. The 79 
guidelines from https://uk.cochrane.org/news/meta-analysis-what-why-and-how were 80 
followed. 81 
Results 82 
Our search identified 21 potentially relevant studies with a total of 4312 ischaemic stroke 83 
and/or TIA patients on Clopidogrel. Study sizes ranged from 62 to 465 stroke or TIA patients.  84 
 5 
Characteristics of the studies are summarised on the Supplementary Table 2. In the overall 85 
analysis of all included studies, the pooled prevalence of HCPR was 28% (95%CI: 24–32%). 86 
However, the prevalence reported between studies presented great variability as 87 
demonstrated by substantial heterogeneity (I2 = 88.2%, Cochran Q p<0.001) (Figure 2). 88 
The main finding is the significant disparity in many aspects across the studies not only in 89 
outcome measure, but also in the patients included, their demographics, the dose of 90 
Clopidogrel, the timing of the tests, the laboratory methods used, the definition of HCPR, and 91 
so on. In order to explain the heterogeneity, we did several analyses by grouping studies 92 
according to factors such as ethnicity (Supplementary Figure 1 and Supplementary Table 2), 93 
and laboratory methods assessing HCPR (Supplementary Table 1 and Supplementary Figure 94 
3). Supplementary Figure 2 refers to subgroup analysis on the prevalence of HCPR according 95 
to use carotid artery stenting.  96 
Heterogeneity only reduced amongst studies using multiple-electrode impedance 97 
aggregometry (MEA), thromboelastography (TEG) and vasodilator-stimulated 98 
phosphoprotein (VASP) methods (Table 1); and   improved with analysis of studies using light 99 
transmission aggregometry (LTA) testing with similar cut-off points defining HCPR 100 
(Supplementary Table 1 and Supplementary Figure 4).  101 
In the analysis of eight studies (total of 1887 IS/TIA patients on clopidogrel) providing data on 102 
outcome including recurrent stroke or other vascular events, increased modified Rankin Scale 103 
(mRS) or National Institutes of Health Stroke Scale (NIHSS) and death, IS/TIA patients with 104 
HCPR had poorer outcome compared to clopidogrel responders (RR = 2.09, 1.61–2.70, 105 
p=0.036) (Figure 3 and Supplementary Table 3).  106 
 6 
From the analysis of eight studies providing data on genotyping, IS/TIA carriers of CYP2C19 107 
loss of function allele (*2 or *3) had a higher risk for HCPR (RR=1.69, 95%CI: 1.47–1.95; 108 
p<0.001; I2=0.01%, p=0.475) (Figure 4). 109 
Discussion 110 
The present report is to our knowledge the first meta-analysis that determines the prevalence 111 
of HCPR in IS/TIA patients and shows a positive association between the presence of HCPR 112 
and poor outcome including recurrent stroke or other vascular events, stroke progression or 113 
death. This finding is consistent with previously published systematic reviews and meta-114 
analyses that reported an increased risk of cardiovascular events in patients with HCPR16. 115 
Meta-analyses in patients with acute coronary syndrome29 who underwent percutaneous 116 
coronary intervention and stenting had a prevalence of HCPR of 21%, with a pooled OR of 117 
cardiovascular events of 8.0, which is similar to our finding.  However, a peripheral vascular 118 
disease30 meta-analysis reported a prevalence of HCPR of 65%, which is much higher than our 119 
result.  120 
There is significant heterogeneity evident across the studies. In particular, the laboratory 121 
methods for testing clopidogrel resistance and the definition of HCPR varied from study to 122 
study. Currently, multiple laboratory and point of care platelet function testing are used 123 
across the world. A recent review31 comparing existing platelet function tests has emphasised 124 
that non-standardised use of these tests and the lack of a proper definition is at least partly 125 
responsible for the disparity of the prevalence reported in studies. In one guideline32 that 126 
attempted to standardise the definition of HCPR, the author argued that cut-off values to 127 
define HCPR are better determined by the individual laboratory, rather than providing an 128 
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arbitrary value generated from previous studies. That report also recommended that multiple 129 
assessments of the patients should be done in the same laboratory if possible, to provide 130 
meaningful interpretation. The same group33 suggested additional clinical information and 131 
genotyping besides a platelet function test may be a better prediction of the risk of recurrent 132 
thromboembolic events.  133 
In all the included studies, there were significant differences in clinical factors such as 134 
ethnicity, age, and co-morbidities, which probably have contributed to the heterogeneity of 135 
the analysis. In subgroup analysis for Asian/Non-Asian, IS/TIA plus or minus carotid artery 136 
stent, this heterogeneity did not dissipate. However, the subgroup analysis of laboratory 137 
methods did show much less heterogeneity, but the number of studies in each group was 138 
small so the results must be interpreted with caution. 139 
A similar pattern of disparity was observed in analysis of the genetic studies. We nevertheless 140 
found that a significant proportion of IS/TIA patients with HCPR were CYP2C19 loss-function 141 
allele carriers. Previous studies showed that among patients with ischemic stroke or TIA 142 
treated with clopidogrel, carriers of CYP2C19 loss-of-function alleles are at increased risk of 143 
new stroke and composite vascular events in comparison with noncarriers, whereas bleeding 144 
risk is similar34. Similarly,  the metanalysis35 of acute coronary syndrome (ACS) patients who 145 
were CYP2C19 loss-of-function carriers, found them to have an increased risk of myocardial 146 
infarct (MI), stent occlusion and ischaemic stroke, which supports the conclusion that 147 
CYP2C19 has an important role in clopidogrel metabolism. However, not all patients with 148 
HCPR develop recurrent vascular events. The factors relating to this may not rest solely on 149 
pharmacokinetic aspects of clopidogrel metabolism but may also involve other genetic 150 
variation36. On the present evidence, CYP2C19 genotyping may be a useful addition to the 151 
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individualised risk assessment to predict whether patients on clopidogrel are more at risk of 152 
recurrent vascular events and merit treatment with an alternative antiplatelet agent. 153 
However, further research is needed to assess the applicability of CYP2C19 genotyping on a 154 
routine basis.  155 
Our study has some limitations. First, none of the studies included in the meta-analysis was a 156 
randomised study. Second, medications including proton pump inhibitors intake data among 157 
studies was scanty and therefore was not included to the meta-analysis. Third, platelet 158 
resistance and clinical outcome was not analysed in CYP2C19 loss of function allele carriers 159 
due to limited data among studies.  160 
Clopidogrel resistance has been described for more than a decade, but the quality of 161 
published studies is so variable and heterogeneous that firmer conclusions from this meta-162 
analysis cannot be drawn. However, patients with HCRP need evidence based guidance on 163 
how to approach their management. In order to determine the true potential benefit of 164 
testing for HCPR in the clinical setting, a randomised multicentre study with a single HCPR 165 
definition and centralised laboratory testing is warranted. 166 
Abbreviations 167 
ACS  acute coronary syndrome 168 
CR  clopidogrel responders 169 
CI  confidence intervals 170 
ES  effect size 171 
HCPR  high on clopidogrel platelet reactivity  172 
IS  ischaemic stroke  173 
 9 
LoF   loss of function   174 
LTA   light transmission aggregometry  175 
MEA  multiple-electrode impedance aggregometry  176 
MI  myocardial infarction 177 
PRISMA  Preferred Reporting Items for Systematic Reviews and Meta-Analyses  178 
RR  risk ratios  179 
TEG  thromboelastography  180 
TIA  transient ischaemic attack  181 
VASP   vasodilator-stimulated phosphoprotein  182 
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Figure 1: Flow chart diagram presenting the selection procedure of eligible studies.  377 
Figure 2: Pooled prevalence of all studies: Heterogeneity chi-squared = 169.69 (d.f. = 20), 378 
p<0.001; I-squared (variation in ES attributable to heterogeneity) = 8788.2%; Estimate of 379 
between-study variance Tau-squared = 0.0069; Test of ES=0 : z= 14.22; p<0.001. References25, 380 
37-56. ID (identification); ES (effect size;) CI, confidence interval. 381 
Figure 3: Overall analysis of all studies providing data on the outcome between non-382 
responders and responders to clopidogrel. References25, 38, 45-48, 50, 55. ID, identification; RR 383 
(relative risk); CI, confidence interval. 384 
Figure 4: HPCR related to CYP2C19 loss of function: Heterogeneity chi-squared =  6.57(d.f. =7) 385 
p = 0.475; I-squared (variation in ES attributable to heterogeneity) =  0.01%; Estimate of 386 
between-study variance Tau-squared =  0.0000; Test of RR=1 : z= 7.32;  p<0.001. References39, 387 
45, 47, 50-53, 55. ID (identification); RR (relative risk); CI (confidence interval). 388 
 389 
Table legends  390 
Table 1. Subgroup analyses on the prevalence of HCPR reported in included studies. 391 
References25, 37-56 392 
Supplementary data 393 
Supplementary Table 1: Laboratory characteristics of the studies included for pooled 394 
proportion analysis. References25, 37-56 395 
Supplementary Table 2: Clinical characteristics of the studies included for pooled proportion 396 
analysis. References25, 37-56 397 
 16 
Supplementary Table 3: Outcome of the HCPR vs clopidogrel responders. References39, 45, 47, 398 
50-53, 55 399 
Supplementary Figure 1: Subgroup analyses on the prevalence of HCPR according to ethnicity. 400 
References25, 37-56. ID (identification); ES (effect size); CI (confidence interval). 401 
Supplementary Figure 2: Subgroup analyses on the prevalence of HCPR according to carotid 402 
artery stenting. References25, 37-56. ID (identification); ES (effect size); CI (confidence interval); 403 
IS (ischaemic stroke); CAS (carotid artery stenting).  404 
Supplementary Figure 3: Subgroup analyses on the prevalence of HCPR according to test. 405 
References25, 37-56. ID (identification); ES (effect size); CI (confidence interval); LTA (light 406 
transmission aggregometry); VASP (vasodilator-stimulated phosphoprotein); TEG 407 
(thromboelastography); MEA (multiple-electrode impedance aggregometry). 408 
Supplementary Figure 4: Subgroup analyses on the prevalence of HCPR according to LTA test 409 
different cut-off points. References 25, 41, 43, 44, 55. ID (identification); ES (effect size); CI 410 
(confidence interval); LTA (light transmission aggregometry); platelet aggregation rate <30% 411 
or <10% are  cut-off points defining HCPR on light transmission aggregation. 412 
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 1 
Table 1. Subgroup analyses on the prevalence of HCPR reported in included studies. 1 
Subgroup analysis Prevalence (95%Cl) I2, Cochran Q 
According to ethnicity  
  Asian 







According to stroke type 
  IS/TIA with CAS  







According to the method  
  VerifyNow System  
  LTA 
  VASP 
  MEA 













HCPR, high on clopidogrel platelet reactivity; LTA, light transmission aggregometry; MEA, 
multiple-electrode impedance aggregometry; TEG, thromboelastography; VASP, 
vasodilator-stimulated phosphoprotein; IS, ischaemic stroke; TIA, transient ischaemic 





Supplementary Table 1. Laboratory characteristics of the studies included for pooled 
proportion analysis. 













18/62 VerifyNow   >7 days <20% NA NA 
Fong (2011) 83/465 LTA NA <40% NA NA 
Fukuoka 
(2011) 
13/72 VerifyNow  >7 days 66% NA NA 
Nordeen 
(2013) 
17/160 VerifyNow  NA <20% NA NA 
Jie (2014) 22/87 LTA >5 days <35% NA NA 
Su (2014) 51/303 LTA >7 days <30% NA NA 
Zhang (2014) 39/95 VASP >7 days >50% 10/5 29/51 
Meves (2014) 50/159 MEA 7 days > 47 NA NA 
Qiu (2015) 53/211 Flow 
cytometry 
7 days >28.54 43/86 10/72 
Han (2015) 122/345 VerifyNow  5-7 days ≥230 76/124 0/136 
Lunsdorm 
(2015) 
16/72 MEA 30 days <468 NA NA 
Yi (2016) 153/426 LTA >7 days <10 % NA NA 
Gonzalez 
(2016) 
99/209 VerifyNow  >7 days ≥230 35/18 64/92 
Li (2017) 78/196 VASP 7 days < 60% 67/89 65/171 
Sun (2017) 46/221 TEG 3-5 days <30% NA NA 
Rao (2017) 53/278 TEG 7 days < 30% 31/115 15/87 
Rosafio (2017) 74/209 MEA 7-10 days <46U 13/21 27/68 
Marginean 
(2017) 
25/101 MEA 5 days >43 7/2 25/56 
Rath (2018) 63/219 VerifyNow  8-24 hours >208 NA NA 
Chen (2018) 65/192 LTA 5-7 days <10% 43/65 20/61 
Lu (2019) 57/230 VerifyNow  7-14 days >50% NA NA 
CR, clopidogrel responders; HCPR, high on clopidogrel platelet reactivity; LTA, light 
transmission aggregometry; MEA, multiple-electrode impedance aggregometry; TEG, 
Supplementary Table 1
 
thromboelastography; VASP, vasodilator-stimulated phosphoprotein; LoF, loss of function that 
is CYP2C19*2 or *3 alleles. 
 
Supplementary Table 2. Clinical characteristics of the studies included for pooled proportion 
analysis. 
Study ID Age (SD) Female% DM % Smoking% Patients  Country 
 
Maruyama (2011) 65.3 (9.9) 32 27 48 IS/CAS Japan 
Fong (2011) 65.6 (13.6) 53 35 NA IS US 
Fukuoka (2011) 69 (8.0) 28 NA NA IS/TIA Japan 
Nordeen (2013) 61 (14.3) 65 41 NA IS/TIA/NV US 
Jie (2014) 62.9 (8.0) 36 18 18 IS China 
Su (2014) 63.65 (9.6) 23 55 13 IS China 
Zhang (2014) 64.8 (11.3) 40 21 31 NCIS China 
Meves (2014) 72.2 (8.8) 30 40 12 AIS Germany 
Qiu (2015) 66.7 (11.5) 47 36 38 AIS China 
Han (2015) 68.1 (11.5) 32 39 NA AIS China 
Lunsdorm (2015) 70 (66-77) 56 31 NA IS/TIA Sweden 
Yi (2016) 69.9 (12.2) 35 52 62 Minor AIS China 
Gonzalez (2016) 67.2 (9.6) 17 47 41 IS/CAS Spain 
Li (2017) 63.67 (11) 29 33 39 NCIS China 
Sun (2017) 59 (8.0) 18 32 62 IS/TIA/CAS China 
Rao (2017) 57.9 (9.5) 26 38 41 Minor 
IS/TIA 
China 
Rosafio (2017) 68.6 (13.9) 36 24 31 ASA Italy 
Marginean (2017) 65.6 (11.1) 81 25 28 NCIS Romania 
Rath (2018) 72.8 (10.9) 46 18 16 IS/TIA Denmark 
Chen (2018) 67.0 (13.1) 42 31 26 IS China 
Lu (2019) 68.5 (7.2) 47 58 30 IS China 
IS, ischaemic stroke; TIA, transient ischaemic attack; NICS, non-cardiogenic ischaemic stroke; 
CAS, carotid artery stenting; NV, neuro-intervention; SD, standard deviation; N, number; NA, 





Supplementary Table 3. Outcome of the HCPR vs clopidogrel responders  














drop outs  
Nordeen (2013) 17/64 5/12 13/51 Stroke/ICH 
recurrence, death  
3 months 
Zhang (2014) 39/56 12/27 6/50 Increase in NIHSS 




vascular events  
6 months 




Qiu (2015) 53/158 9/44 6/152 Stroke 
recurrence, 
nonfatal MI and 
CVD death, 
mRS<2 vs mRS>2  
6 months 
Han (2015) 90/181 29/61 31/150 Stroke/ICH 
recurrence 
12 months 




Li (2017) 77/118 22/55 15/104 Increase of NIHSS 
score ≥ 2, 
vascular events  
6 months 




HCPR, high on clopidogrel platelet reactivity; ICH, intracranial hemorrhage; NIHSS, National 
Institutes of Health Stroke Scale; mRS, modified Rankin Scale; MI, myocardial infarction; CVD, 
cardiovascular disease. 
Supplementary Table 3
